June 29, 2016 – The saga goes on: The American  Food & Drug Administration (FDA) just approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) infection both with and without cirrhosis (advanced liver disease). For patients with …

The HCV saga goes on: Epclusa has been approved for treatment of chronic Hepatitis C virus (HCV) infection Read more »

May 30, 2016 – According to its News and Events section of the homepage, the European Medicines Agency (EMA) has recommended the granting of marketing authorisations in the European Union (EU) for two new combination therapies against chronic (long-term) hepatitis C virus (HCV) infection, namely …

EMA: Two new combination therapies against chronic hepatitis C recommended for approval Read more »

January 30, 2016 – Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV have no symptoms of the disease until liver damage becomes …

Elbasvir/Grazoprevir (Zepatier) for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections Read more »